From the Polynovo update:
This pilot human trial is designed to evaluate the feasibility of replacing the current non-degradable VAC device wound interface with a NovoSorb product. Key elements of the trial protocol to test the safety and suitability of the NovoSorbTM product will be as follows:
• 20 patients randomised with10 using NovoSorbTM and 10 using Granufoam® dressings;
• The current standard of care including 3 dressing changes per week will be adopted;
• Treatment duration of up to 8 weeks, less if the wound bed is suitable for definitive closure by skin graft;
• Disease indication - Sacral pressure sores; and
• Single study site (Royal Adelaide Hospital)
The open question is this: If dressings are to be changed three times a week, what therapeutic advantage is expected from using a biodegradable Novosorb dressing?
- Forums
- ASX - By Stock
- CZD
- open question - vac study
open question - vac study
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CZD (ASX) to my watchlist
Currently unlisted public company.